Literature DB >> 11595659

Mechanisms of insulin resistance in cystic fibrosis.

D S Hardin1, A Leblanc, G Marshall, D K Seilheimer.   

Abstract

Cystic fibrosis (CF) is associated with a high incidence of diabetes. Studies evaluating causes of CF-related diabetes (CFRD) have consistently documented decreased insulin secretion. In patients with CFRD, insulin sensitivity has been documented to be decreased, but controversy exists in patients with normal or impaired glucose tolerance (IGT). We undertook this study 1) to reexplore insulin sensitivity in patients with IGT and 2) to evaluate potential mechanisms of insulin resistance in CF, including GLUT-4 translocation, elevation of serum cytokines, and free fatty acid (FFA) levels. We recruited nine CF subjects with impaired glucose tolerance (IGTCF) and nine age-, gender-, and body mass index-matched control volunteers. Each underwent a hyperinsulinemic euglycemic clamp (200 mU. m(-2). min(-1)) to measure insulin sensitivity. A muscle biopsy was obtained at maximal insulin stimulation for measure of GLUT-4 translocation with sucrose gradients. An oral glucose tolerance test and National Institutes of Health (NIH) clinical status scores were measured in all volunteers. We also measured tumor necrosis factor (TNF)-alpha levels and FFA in all subjects. Additionally, we report the results of TNF-alpha and FFA in 32 CF patients previously studied by our group. Results were that glucose disposal rate (GDR) was significantly lower in the CFIGT subjects than in controls, indicative of impaired insulin action. GLUT-4 translocation was impaired in CF and correlated with GDR. TNF-alpha levels were higher in all CF subjects than in controls and correlated with GDR. There was no difference in FFA between CF and control subjects. Modified NIH clinical status scores were inversely correlated with GDR and TNF-alpha levels. We conclude that IGTCF patients have decreased peripheral insulin sensitivity. Mechanisms include elevation of TNF-alpha and impaired translocation of GLUT-4.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595659     DOI: 10.1152/ajpendo.2001.281.5.E1022

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  17 in total

Review 1.  Routine screening for cystic fibrosis-related diabetes.

Authors:  Daniel Peckham
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

2.  Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy.

Authors:  Andrea Kelly; Diva D De Leon; Saba Sheikh; Devaney Camburn; Christina Kubrak; Amy J Peleckis; Darko Stefanovski; Denis Hadjiliadis; Michael R Rickels; Ronald C Rubenstein
Journal:  Am J Respir Crit Care Med       Date:  2019-02-01       Impact factor: 21.405

3.  Insulin production and resistance in cystic fibrosis: effect of age, disease activity, and genotype.

Authors:  M E Street; C Spaggiari; M A Ziveri; M Rossi; C Volta; I Viani; G L Grzincich; C Sartori; M Zanzucchi; V Raia; C Terzi; G Pisi; E Zanetti; M C S Boguszewski; T O Kamoi; S Bernasconi
Journal:  J Endocrinol Invest       Date:  2011-04-06       Impact factor: 4.256

4.  Reduced insulin sensitivity is correlated with impaired sleep in adolescents with cystic fibrosis.

Authors:  Stacey L Simon; Tim Vigers; Kristen Campbell; Laura Pyle; Rachael Branscomb; Kristen J Nadeau; Christine L Chan
Journal:  Pediatr Diabetes       Date:  2018-08-01       Impact factor: 4.866

5.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

6.  Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions.

Authors:  Neda Rasouli; Stacey Seggelke; Joanna Gibbs; R Matthew Hawkins; Matthew L Casciano; Elizabeth Cohlmia; Jennifer Taylor-Cousar; Cecilia Wang; Rocio Pereira; Elisa Hsia; Boris Draznin
Journal:  J Diabetes Sci Technol       Date:  2012-09-01

7.  OGTT-derived measures of insulin sensitivity are confounded by factors other than insulin sensitivity itself.

Authors:  Katrin Hücking; Richard M Watanabe; Darko Stefanovski; Richard N Bergman
Journal:  Obesity (Silver Spring)       Date:  2008-07-10       Impact factor: 5.002

Review 8.  Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.

Authors:  Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

9.  AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells.

Authors:  Michael M Myerburg; J Darwin King; Nicholas M Oyster; Adam C Fitch; Amy Magill; Catherine J Baty; Simon C Watkins; Jay K Kolls; Joseph M Pilewski; Kenneth R Hallows
Journal:  Am J Respir Cell Mol Biol       Date:  2009-07-17       Impact factor: 6.914

10.  Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain.

Authors:  Shihab Hameed; John R Morton; Adam Jaffé; Penny I Field; Yvonne Belessis; Terence Yoong; Tamarah Katz; Charles F Verge
Journal:  Diabetes Care       Date:  2009-11-12       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.